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ABSTRACT
Cyclic AMP response element binding protein (CREB)
activates transcription of cAMP response element
(CRE)-containing promoters following an elevation of
intracellular cAMP. Here we show that CREB and the
highly related protein ATF-1 are also potent
transcription inhibitors. Strikingly, CREB inhibits
transcription of multiple activators, whose DNA-binding
domains and activation regions are unrelated to one
another. Inhibition requires that the CREB dimerization
and DNA-binding domains are intact. However,
inhibition is not dependent upon the presence of a CRE
in the promoter, and does not involve heterodimer
formation between CREB and the activator. The ability
of an activator protein to inhibit transcription in such
a promiscuous fashion has not been previously
reported.
INTRODUCTION
Transcription in eukaryotes is under negative as well as positive
control. Several mechanisms for negative regulation
(transcriptional repression) have been proposed (reviewed in 1,
2) and include: competition between the inhibitor and the activator
for a common promoter binding site (steric occlusion); titration
by the inhibitor of the activator's target (e.g. squelching);
formation of an inactive activator/inhibitor complex; inhibition
of DNA-bound activator by a DNA-bound repressor. These
previously described inhibitory mechanisms are dependent upon
specific features of the activators, specific elements in the target
promoter, or both.
The cAMP response element binding protein CREB (3) is a
member of the ATF/CREB family of transcription factors. These
proteins bind to highly related DNA sites and possess homologous
'bZIP' domains which consist of a DNA-binding region rich in
basic amino acids and a leucine zipper dimerization domain (4,
5). CREB activates transcription of cAMP response element
(CRE)-containing genes following an elevation of intracellular
cAMP (reviewed in 6). CREB is a substrate for protein kinase
A (PKA) and phosphorylation of serine 133 is required for
activation (7). CREB can also inhibit transcription of specific
promoters. In these instances repression requires specific
promoter elements and is relieved by PKA phosphorylation (8, 9).
Here we show that CREB can inhibit transcription of unrelated
activators in a manner that does not require specific promoter
elements and that does not involve a PKA-dependent pathway.
MATERIALS AND METHODS
Cell cultures and transfection
Monkey kidney CV-1 cells were grown in Dulbecco's modified
Eagle medium supplemented with 10% foetal bovine serum. For
transfection experiments, we followed the calcium-phosphate co-
precipitation procedure. Subconfluent cells were split 1:8 and
plated on 60 mm dishes 24 hrs before transfection. Transfection
was performed with 2,Ag of reporter plasmid and various amounts
of activator coding plasmids as indicated in the figure legends.
The total amount of DNA was adjusted to 8 yg with pGEM-3
(Pharmacia). The cells were exposed for 11-12 hrs to the
precipitate, washed and further incubated with medium for 24
hrs before harvest. The transfections were performed at least four
times with at least two different plasmid preparations for each
plasmid.
Plasmids
p(GAL4)2-Elb-CAT (10), pL6EC (10), pGAL4-VP16 (11),
pLexA-VP16 (10) and pECE-ATF2 (12) are described. The
constructs coding for CREB and CREB mutants are described
in (7, 13, 14). pGAL4-ATF4 was constructed by amplifying the
full-length ATF-4 cDNA by the polymerase chain reaction and
cloning the fragment in the BamHI and XbaI sites of pSG424
(15). pGAL4-ATF4(1-56) was made by deleting a Banl-BamHI
fragment from pGAL4-ATF4. pGAL4-EIA(140-182) contains
the coding sequences for amino acids 140 to 182 of the adenovirus
5 ElA protein inserted in the EcoRI site of pSG424. pGAIA-Pro
codes for amino acids 1 to 94 of GAL4 upstream of the amino
acids 399 to 499 of CTF/NF-I and was constructed by inserting
a XhoI-XbaI fragment of pGAL4-Pro (16).
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Immunoblotting
CV-1 cells were transfected in duplicate. When harvesting the
cells, the duplicates were mixed, then split again in two. One
half of the cells were tested for chloramphenicol acetyl transferase
(CAT) activity, the other half was resuspended in loading dye
and boiled for 10 minutes before loading on a 10% SDS-
polyacrylamide gel. The proteins were transfered to a nylon
membrane by semi-dry blotting using the Semi-Phor (Hoefer)
blotter and detected with an antibody directed against
GAL4(1-147).
RESULTS
Our initial observations were based upon experiments with the
protein ATF-4. ATF-4 is a member of the ATF/CREB family
and contains a bZIP DNA-binding domain. Using a partial ATF-4
cDNA clone (4) we isolated a full length ATF-4 cDNA from
a human placenta Xgtl 1 library. The full-length ATF-4 sequence
is identical to a previously described ATF protein, designated
TAXREB67 (17).
We analyzed the transcriptional activity of ATF-4 in
cotransfection experiments. Because all cell lines examined to
date contain high levels ofATF proteins, we reprogrammed the
DNA-binding secificity of ATF-4 by fusing its full-length cDNA
in-frame to the coding sequences of the yeast GAL4 DNA-binding
domain (amino acids 1 to 147). A plasmid expressing G-
AL4-ATF4 was cotransfected into CV-1 cells with a reporter
plasmid containing the CAT gene downstream of a synthetic
AM
promoter containing a consensus TATA box (Adenovirus Elb)
and two GAL4 binding sites (see Fig.2B). Fig.lA shows that
GAL4-ATF4 activated transcription (lane 2), indicating that it
contains a constitutive activation region. To our knowledge
ATF-4 is the first example of an ATF protein with a constitutive
activation domain.
We next sought to determine whether other ATF proteins can
affect the activity of ATF-4. Fig. lA shows unexpectedly that
transcriptional stimulation by GAL4-ATF4 was strongly inhibited
(> 30-fold) by cotransfection of a plasmid expressing either
CREB (3) (lane 3) or the highly related protein ATF-1 (4)(lane
4). Significantly, the amount of transfected CREB expression
plasmid required for inhibition is comparable to that required
for activation of a CRE-containing promoter (see also Fig.6 and
data not shown). In contrast, inhibition was not observed upon
cotransfection of an ATF-2 expressing plasmid (18)(Fig. 1A, lane
5), indicating that not all ATF/CREB proteins have inhibitory
activity. Comparable inhibition was observed when lower
amounts of reporter plasmid were transfected (data now shown).
One potential class of inhibitory mechanisms involve
heterodimerization: ATF proteins, such as ATF-4 and CREB,
contain leucine zipper dimerization motifs (4). Conceivably, some
ATF heterodimer combinations are transcriptionally inactive. To
address this possibility we asked whether CREB would inhibit
a GAL4-ATF4 derivative that could not heterodimerize. The N-
terminus of ATF-4 contains multiple acidic amino acids (Fig. 1B,
bottom) and in particular the region 25 to 45 is acidic and contans
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Flgure 1. CREB and ATF-1 can fimcton astanson inhibitors. (A) Activity
ofGAL4-ATF4 in the presence ATF proteins. The presence (+) or absence (-)
of the GAL4-ATF4 expression plasmid is shown below each lane. The
cotansfected ATF expression plasnid is indcated above each lane. For a schematic
representation of the reporter plasmid, see Fig.2B. (B) Activity of
GAL4-ATF4(1-56) in the presence of CREB. As in part A. Below the
autradiogram is shown ATF-4 amino acids 1-56 with acidic residues undelined.
Transfection was performed with 2 yg of p(GAL4)2-Elb-CAT reporter, 1 &g
pGAL4-ATF4 or pGAL4-ATF4(1-56) and 2 yg pECE-ATFl, pECE-ATF2 or
pRSV-CREB.
F%gure 2. CREB inhibits activators containing unrelated transcriptional activation
and DNA-binding regions. (A) Transfection of GAL4-VP16, GAL4-E1A,
GAL4-Pro and LexA-VP16 constructs in the presence of CREB. The presence
(+) or absence (-) of the CREB expression plasmid is indicated below the
autoradiogram. The cotransfected acdvator expression plasmid and remer plasmid
is indicated below the autoradiogram. (B) Structure of the reporters and activator
proteins. Transfections were performed as in Fig. 1 with 1 ng of pGAL4-VP16,
1 ng pLex-VP16, 50 ng of pGAL4-ElA(140-182) or 2 MAg of pGAL4-Pro, and
2 Mg of p(GAL4)2-Elb-CAT reporter or pL6EC, in the presence or absence of
2 MAg of pRSV-CREB.
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a short potential helical structure reminiscent of some acidic
activation domains (19). Indeed, a GAL4 fusion protein
containing ATF-4 residues 1-56, GAL4-ATF4(1 -56), activated
transcription (Fig. lB, lane 2). Significantly, cotransfection of a
CREB expression plasmid also inhibited GAL4-ATF4(1-56)
(Fig. iB, lane 3). This result strongly argues that inhibition does
not involve heterodimerization through their leucine zipper motif:
GAL4-ATF4(1-56) lacks the leucine zipper and instead
dimerizes through a region in GAL4(1-147).
To determine whether inhibition was specific to GAL4-ATF4,
we analyzed GAL4 fusion proteins containing well characterized
acidic and non-acidic activation regions. GAL4 fusion proteins
containing the acidic activation domain of the HSV1 VP16 protein
(amino acids 412 to 490), the metal-binding activation domain
of the adenovirus 5 EIA protein (amino acids 140 to 182) or
the proline-rich activating region of CTF/NF-I (amino acids 399
to 499), all stimulated transcription to varying extents (Fig.2).
Significantly, CREB inhibited transcription directed by all three
activators. Fig.2 also shows that CREB inhibited LexA-VP16,
indicating that inhibition did not require the GAL4 DNA-binding
domain. Inhibition by CREB occured in several unrelated cell
lines (data not shown), indicating that no species- or tissue-specific
factor was involved.
One way by which CREB could inhibit transcription in this
assay is to block expression of the activator. To address this
possibility we measured the effect of CREB on the steady-state
levels of three of the GAL4 derivatives analyzed in Fig.2. Fig.3
shows in an immunoblot assay that upon cotransfection of the
CREB expression plasmid, the levels of GAL4-VP16 and G-
AL4-E1A were unchanged, while the level of GAL4-Pro was
decreased only 2-fold. This modest decrease cannot account for
the much stronger (> 30-fold) inhibition we observed:
transfection and assay conditions were performed in the linear
range.
To gain insight into the mechanism of inhibition we analyzed
several well characterized CREB derivatives (7, 13, 14) (Fig.4).
Previous studies have shown that these derivatives are expressed
at comparable levels in transfected cells (7, 13, 14). Fig.4 shows
that a CREB derivative with a disrupted leucine zipper (CREB
ALZ) failed to inhibit GAL4-ATF4 (lane 4). Remarkably, a single
amino-acid substitution within the basic region of CREB's bZIP
DNA-binding domain (CREBK304E), which abolishes DNA-
binding (13), also eliminated inhibition (lane 5). We conclude
that inhibition by CREB requires intact dimerization and DNA-
..... 30
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Figure 3. CREB does not affect the steady-state levels of the activators. The
presence (+) or absence (-) of the CREB expression plasmid is shown below
each lane. The cotransfected activator expression plasmid is indicated below the
autoradiogram. CV-1 cells were transfected as in Fig.l with 2 iog p(GAL4)2-Elb-
CAT reporter alone (lane 1), reporter and 1 lAg pGAIA-VP16 (lanes 2-3), or
pGAL4-ElA (lanes 4-5) or pGAL4-Pro (lanes 6-7) in the presence (lanes 3,
5 and 7) or absence (lanes 1, 2, 4 and 6) of 2 jg pRSV-CREB.
binding domains. In contrast, two CREB derivatives with
impaired transcriptional activation regions inhibited GAL4-ATF4
directed transcription: these included ACREB (lane 7), the natural
variant of CREB that contains a 14 amino acids deletion of the
so-called ca-peptide (14), and a point mutation at serine 133 in
the PKA motif (7) (CREBM1) (lane 6). Identical results were
obtained with these CREB derivatives when the activator was
GAL4-VP16, rather than GAL4-ATF4 (data not shown).
To rule out the possibility that inhibition was due to binding
of CREB to a putative 'cryptic' CRE adventitiously present in
the promoters described above, we tested the ability of CREB
to inhibit transcription from two completely unrelated promoters.
We have previously shown that a GAL4-Tat fusion protein can
activate transcription from a Human Immunodeficiency Virus
(HIV) LTR derivative containing GAL4 binding sites (20).
Figure 5A shows that activation by GAL4-Tat was completely
inhibited by CREB. Figure 5B shows that CREB could also
partially inhibit transcription directed by the powerful SV40 early
promoter. Significantly, the effect of CREB mutants on inhibition
of the SV40 early promoter paralleled the results of Figure 4.
Thus, these combined data indicate that CREB could inhibit
transcription of several completely unrelated promoters, strongly
arguing that inhibition was not due to a cryptic CRE.
Activation of transcription by CREB involves phosphorylation
by PKA (7). We therefore tested whether PKA affected CREB's
ability to inhibit transcription (Fig.6). Cells were transfected with
a constant amount of a plasmid expressing GAL4-VP16 and
increasing amounts of the CREB expression plasmid. Twelve
hours before harvest cells were treated with forskolin and
3-isobutyl-1-methyl-xanthine (IBMX) to raise intracellular cAMP.
Fig.6 shows that increasing the intracellular cAMP concentration
did not affect inhibition at any level of CREB. Identical results
A. qib +
* ,,*
GAL4-ATF4 - + + + + + +
B.
ii -~ [-
DNA-binding Leucine
domain zipper
CREB m t-
CREB ALZ VA ZZZL
CREB K304E E t
Lys 304 _ Glu
CREB Ml I m I F
Ser133-_- Ala
ACREB
Figure 4. Transcription inhibitory activity of CREB derivatives. (A) Activity
of GAL4-ATF4 in the presence of CREB derivatives. As in Fig. 1. (B) Schematic
representation of the CREB derivatives. 1 ,ug of pGAL4-ATF4 was cotransfected
with 2 izg p(GAL4)2-Elb-CAT reporter and 2 yg of each of the CREB coding
plasmids as described in Fig. 1.
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Figure S. CREB inhibits transcription directed by other promoters. (A) An HIV
LTR Derivative. The presence (+) or absence (-) of GAL4-Tat and CREB
expression plasmids is indicated. The structures of the reporter and GALA-Tat
are indicated below the autoradiogram. Transfections were performed as in
Figure 1 with 2 jg of pG6(-83) HIV LTR ATAR-CAT, in the presence or
absence of 10 ng pGAL4-Tat or 2 Ag of pRSV-CREB. (B) The SV40 early
promoter. 1 Ag pSV2CAT was co-transfected with 2 Mg of plasmid encoding the
CREB derivatives, the structures of which are shown in Figure 4.
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Figure 6. Intracellular cAMP does not affect the ability of CREB to inhibit
transcription. The presence (+) or absence (-) of the GALM-VP16 expression
plasmid is shown below each lane. The amount of cotransfected CREB expression
plasmid, and the presence (+) or absence (-) of forskolin and IBMX is indicated
above. Cells were transfected as in Fig. 1 with 2 Mg (GAL4)2-Elb-CAT reporter
plasmid, 1 ng pGAL4-VP16 and pRSV-CREB as indicated above the lanes.
Forskolin (15 MM) and IBMX (0.5 mM) were added to the medium during 12
hrs prior harvest. The sensitivity of the cells to forskolin and IBMX was controlled
by an independent transfection of a CRE-containing vasoactive peptide promoter-
CAT construct (not shown).
were obtained when intracellular cAMP concentration was raised
by cotransfecting a plasmid expressing PKA (data not shown).
We therefore conclude that inhibition of transcription by CREB
does not involve a PKA-dependent pathway.
DISCUSSION
In this paper we show that CREB and ATF-l can inhibit activation
by diverse classes of transcription factors, whose DNA-binding
and activating regions are unrelated to one another. This inhibition
requires intact CREB dimerization and DNA-binding domains,
and does not involve phosphorylation of CREB by PKA. Below
we discuss several possible models for how CREB could inhibit
transcription in such a promiscuous fashion.
One possibility is that CREB inhibits transcription by a
squelching type of mechanism (21). While difficult to rule out
absolutely, for several reasons we do not favor this idea. For
example, the activation domain of CREB has been mapped and
is separable from the bZIP DNA binding domain (22). We find
that a single amino acid substitution in the basic region, and an
in-frame deletion of the leucine zipper, eliminated inhibition by
CREB; if squelching was the inhibitory mechanism these
mutations would be predicted to either have no effect or perhaps
even to increase inhibition. Conversely, mutations within the
known activation region of CREB did not significantly affect its
ability to inhibit transcription.
An alternative model for inhibition would involve direct binding
of CREB within the vicinity of the target promoter. We again
do not favor this model for several reasons. First, the reporter
plasmids used in these experiments contain synthetic promoters,
which lack a CRE. Second, inhibition was observed using several
different promoters that are completely unrelated to one another.
Third, if a cryptic CRE were reponsible for inhibition we would
expect that relatively high levels of CREB would be required
for inhibition. However, the amount of transfected CREB
expression plasmid required to inhibit transcription was
comparable to that required to activate a consensus CRE-
containing promoter. Finally, the possibility that the reporters
contain a cryptic CRE would still not explain why CREB
inhibited, rather than activated, transcription particularly in the
forskolin induction experiment of Figure 6.
A final possible inhibitory mechanism would involve direct
interaction between CREB and the activators. This also seems
implausible: inhibition was observed with activators containing
unrelated DNA-binding domains and activation regions.
The model we favor is premised on the observation that
mutations in the basic region and leucine zipper of CREB
eliminated inhibition, suggesting that inhibition requires DNA
binding. However, as discussed above, in our experiments the
repressed promoters lack a CRE, suggesting that the target CRE
must be present elsewhere. Based upon these considerations, we
suggest a working model in which CREB binds to a CRE in a
cellular promoter and down-regulates a gene encoding an essential
transcription factor. For example, CREB could block binding
of a positively-acting ATF protein, or antagonize a DNA-bound
activator required for expression of the putative cellular gene.
This proposal does not imply that CREB will inhibit all
promoters equally. For example, we have found that CREB only
partially inhibits the strong SV40 early promoter/enhancer
(Figure SB). Differences in the level of inhibition may reflect,
for example, variable abilities of promoters to compete for a
limiting transcription component. Alternatively, recent studies
indicate that promoters may differ in their requirements for some
basic transcription factors (23). These possibilities could explain
how CREB, a potent transcription activator, avoids repressing
itself when activating a CRE-containing promoter. The difference
between CREB's ability to activate or inhibit transcription may
also be related to phosphorylation. Although inhibition by CREB
does not appear to be modulated by PKA, we do not rule out
the possible role of other phosphorylation events: CREB contains
potential phosphorylation sites for several kinases (22, 24, 25).
Finally, the ability of CREB to activate or inhibit transcription
may be dependent on promoter context, i.e., the other
transcription factors bound to the promoter. For example, CREB
can modulate the activity of the somatosatin promoter in a
phosphorylation-independent fashion (26).
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There have been several previous reports that a specific
ATF/CREB protein could repress transcription of a particular
target promoter (8, 9, 27, 28). However, in these instances
repression required a CRE/ATF site in the target promoter (27,
28), or inhibition was relieved by PKA phosphorylation (8, 9).
It therefore seems unlikely that the relatively specific repression
observed in these previous studies is related to the more general
inhibition described here. In any case, it is evident that CREB
can either activate or repress transcription dependent upon
particular circumstances such as the target promoter. Other
transcription regulators, such as the YY1/NF-E1/6 protein (29),
steroid receptors and AP-1 (30-33) can also either activate or
repress transcription in different promoter contexts.
It is interesting to speculate upon the role of CREB's
transcriptional inhibitory activity. Increased intracellular cAMP
acts through CREB to preferentially induce a set of proteins, such
as neuropeptides, that are expressed from CRE-containing
promoters. Repression by CREB may represent the
complementary component of this transcriptional induction: by
repressing transcription of some cellular genes CREB facilitates
the selective expression of cAMP-inducible genes. Similarly,
induction of gene expression in response to heat-shock also
involves both positive and negative regulation (34).
22. Lee, C.Q., Yun, Y., Hoeffler, J.P. and Habener, J.F. (1990) EMBO J.,
9, 4455-4465.
23. Parvin, J.D., Timmers, H.T.M. and Sharp, P.A. (1992) Cell, 68,
1135-1144.
24. Gonzalez, G.A., Menzel, P., Leonard, J., Fischer, W.H. and Montminy,
M.R. (1991) Mol. Cell. Biol., 11, 1306-1312.
25. Sheng, M., Thompson, M.A. and Greenberg, M.E. (1991) Science, 252,
1427-1430
26. Leonard, J., Serup, P., Gonzales, G., Edlund, T. and Montminy, M. (1992)
Proc. Natl. Acad. Sci. USA, 89, 6247-6251.
27. Foulkes, N.S., Borelli, E. and Sassone-Corsi, P. (1991) Cell, 64, 739-749.
28. Karpinsky, B.A., Morle, G.D, Huggenvik, J., Uhler, M.D. and Leiden,
J.M. (1992) Proc. Nati. Acad. Sci. (USA), 89, 4820-4824
29. Shi, Y., Seto, E., Chang, L-S. and Shenk, T. (1991) CeU, 67, 377-388.
30. Jonat, C., Rahmsdorf, H.J., Park, K.-K., Cato, A.C.B., Gebel, S., Ponta,
H. and Herrlich, P. (1990) Cell, 62, 1189-1204.
31. Yang-Yen, H.-F., Chambard, J.-C., Sun, Y.-L., Smeal, T. Schmidt, T.J.,
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32. Schuile, R., Rangarajan, P., Kliewer, S., Ransone, L.J., Bolado, J., Yang,
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